MA34732B1 - Spiro-oxindoles antagonistes de mdm2 - Google Patents

Spiro-oxindoles antagonistes de mdm2

Info

Publication number
MA34732B1
MA34732B1 MA36005A MA36005A MA34732B1 MA 34732 B1 MA34732 B1 MA 34732B1 MA 36005 A MA36005 A MA 36005A MA 36005 A MA36005 A MA 36005A MA 34732 B1 MA34732 B1 MA 34732B1
Authority
MA
Morocco
Prior art keywords
oxindoles
mdm2
spiro
antagonists
compounds
Prior art date
Application number
MA36005A
Other languages
English (en)
Inventor
Shaomeng Wang
Yujun Zhao
Wei Sun
Sanjeev Kumar
Lance Leopold
Laurent Debussche
Cedric Barriere
Jean-Christophe Carry
Kwame Amaning
Ming Guo
Original Assignee
Univ Michigan
Ascenta Licensing Corp
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Ascenta Licensing Corp, Sanofi Sa filed Critical Univ Michigan
Publication of MA34732B1 publication Critical patent/MA34732B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés, des compositions, et des procédés dans le domaine de la chimie médicinale. Les composés et compositions présentement décrits concernent des spiro-oxindoles qui ont une fonction d'antagonistes de l'interaction entre p53 et MDM2, et leur utilisation en tant qu'agents thérapeutiques pour le traitement du cancer et d'autres maladies.
MA36005A 2010-11-12 2013-06-10 Spiro-oxindoles antagonistes de mdm2 MA34732B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41309410P 2010-11-12 2010-11-12
US201161451968P 2011-03-11 2011-03-11
US201161451958P 2011-03-11 2011-03-11
US201161470992P 2011-04-01 2011-04-01
PCT/US2011/060300 WO2012065022A2 (fr) 2010-11-12 2011-11-11 Spiro-oxindoles antagonistes de mdm2

Publications (1)

Publication Number Publication Date
MA34732B1 true MA34732B1 (fr) 2013-12-03

Family

ID=46048358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36005A MA34732B1 (fr) 2010-11-12 2013-06-10 Spiro-oxindoles antagonistes de mdm2

Country Status (27)

Country Link
US (2) US8680132B2 (fr)
EP (1) EP2638046A4 (fr)
JP (1) JP2014500870A (fr)
KR (1) KR101929188B1 (fr)
CN (1) CN103298818B (fr)
AR (1) AR083849A1 (fr)
AU (1) AU2011326395B2 (fr)
CA (1) CA2817585A1 (fr)
CO (1) CO6721010A2 (fr)
CR (1) CR20130271A (fr)
DO (1) DOP2013000104A (fr)
EA (1) EA201390682A1 (fr)
EC (1) ECSP13012678A (fr)
GT (1) GT201300118A (fr)
IL (1) IL226275A0 (fr)
MA (1) MA34732B1 (fr)
MX (1) MX2013005238A (fr)
NI (1) NI201300041A (fr)
NZ (1) NZ611866A (fr)
PE (1) PE20140408A1 (fr)
PH (1) PH12013500955A1 (fr)
SG (1) SG190230A1 (fr)
TW (1) TWI535723B (fr)
UA (1) UA109464C2 (fr)
UY (1) UY33725A (fr)
WO (1) WO2012065022A2 (fr)
ZA (1) ZA201304042B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
CA2939778C (fr) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilises et utilisations de ceux-ci
CA2682174C (fr) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Polypeptides cousus
KR20120099462A (ko) * 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
KR20130099938A (ko) 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
BR112013028983A2 (pt) 2011-05-11 2017-02-07 Sanofi Sa antagonistas mdm2 espiro-oxindol
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
EP2752191A1 (fr) 2013-01-07 2014-07-09 Sanofi Compositions et procédés utilisant un antagoniste de hdm2 et un inhibiteur de mek
WO2014115080A1 (fr) 2013-01-22 2014-07-31 Novartis Ag Composés pyrazolo[3,4-d]pyrimidinone utilisés en tant qu'inhibiteurs de l'interaction p53/mdm2
WO2014115077A1 (fr) 2013-01-22 2014-07-31 Novartis Ag Composés de purinone substitués
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
ES2656471T3 (es) 2013-05-28 2018-02-27 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades
ES2650562T3 (es) 2013-05-28 2018-01-19 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades
US9550796B2 (en) 2013-11-21 2017-01-24 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
EP3099380B1 (fr) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Procédés et compositions permettant de tuer les cellules sénescentes et de traiter les maladies et les troubles associés à la sénescence
MX373045B (es) 2014-04-17 2020-05-26 Univ Michigan Regents Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
ES2959097T3 (es) 2014-08-18 2024-02-20 Hudson Biopharma Inc Espiropirrolidinas como inhibidores de MDM2
MX373033B (es) 2014-08-21 2020-05-27 Boehringer Ingelheim Int Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2016154058A1 (fr) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
EP3359542B1 (fr) 2015-10-09 2021-03-17 Boehringer Ingelheim International GmbH Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53
CN105693738A (zh) * 2016-01-14 2016-06-22 绍兴文理学院 3’-苯基螺[吲哚啉-3,2’-吡咯烷]-2-酮类衍生物及其制备方法和应用
CN113788818A (zh) 2016-04-06 2021-12-14 密执安大学评议会 Mdm2蛋白质降解剂
AU2017246453A1 (en) 2016-04-06 2018-11-08 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN107652296B (zh) * 2016-07-26 2020-08-04 南开大学 螺环氧化吲哚酰腙衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
US10471154B2 (en) 2016-08-08 2019-11-12 Fei Xiao Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
RU2762573C2 (ru) 2016-11-15 2021-12-21 Новартис Аг Доза и режим введения для ингибиторов взаимодействия hdm2 с p53
US9822128B1 (en) 2017-06-01 2017-11-21 King Saud University Substituted spirooxindoles
EA202091583A1 (ru) * 2017-12-29 2020-10-08 Ган Энд Ли Фармасьютикалз Соединения, которые могут применяться в качестве ингибитора опухоли, способ их получения и их применение
CN109988070B (zh) * 2017-12-29 2022-07-26 南京富润凯德生物医药有限公司 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用
EP3511334A1 (fr) * 2018-01-16 2019-07-17 Adamed sp. z o.o. Composés de 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole] -2,3'-dione comme agents thérapeutiques activant le tp53
EP3863720A1 (fr) 2018-10-08 2021-08-18 The Regents Of The University Of Michigan Agents de dégradation de protéine mdm2 à petites molécules
MX2022011602A (es) 2020-03-19 2023-01-04 Kymera Therapeutics Inc Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos.
US12540141B2 (en) 2020-11-23 2026-02-03 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CA3202764A1 (fr) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux derives de spiropyrrolidine
WO2022159644A1 (fr) * 2021-01-23 2022-07-28 Newave Pharmaceutical Inc. Modulateur spirocyclique de mdm2 et ses utilisations
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架
CN115215872A (zh) * 2021-04-15 2022-10-21 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US12145941B2 (en) 2021-12-08 2024-11-19 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
CN116283701B (zh) * 2021-12-21 2025-04-22 中国科学院上海药物研究所 具有4-(取代氨甲基)-5-新戊基-n-取代基吡咯烷-2-甲酰胺结构的化合物
US12145942B2 (en) 2022-04-05 2024-11-19 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN118047784B (zh) * 2022-10-13 2025-09-16 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物
WO2024240858A1 (fr) 2023-05-23 2024-11-28 Valerio Therapeutics Molécules protac dirigées contre un système de réparation de dommages à l'adn et leurs utilisations

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219661A (en) 1962-12-14 1965-11-23 Warner Lambert Pharmaceutical Spirooxindole and spirodehydroindole alkaloids and process therefor
GB1056537A (en) 1963-07-16 1967-01-25 Smith Kline French Lab Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
RU2084449C1 (ru) 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
US5773455A (en) 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP0989856B1 (fr) 1997-01-20 2010-05-12 IMMODAL PHARMAKA GESELLSCHAFT m.b.H. Procede et substances pour liberer un facteur de croissance issu des cellules endotheliales, facteur de croissance libere selon ce procede, et son utilisation
EP1015430A4 (fr) 1997-09-08 2001-01-17 Arqule Inc Composes de spiro pyrrolidine-2,3'-oxindole] et procedes d'utilisation
WO2000011470A1 (fr) 1998-08-20 2000-03-02 Chugai Seiyaku Kabushiki Kaisha Procede de criblage de composes d'interet potentiel destines a un medicament contre les tumeurs
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
CN1182083C (zh) 2001-10-08 2004-12-29 廖宜芳 一种杀虫灭菌的配位肥及其制造方法
WO2003051360A1 (fr) 2001-12-18 2003-06-26 F. Hoffmann-La Roche Ag Cis-imidazolines inhibiteurs de mdm2
DE60225719T2 (de) 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
JP4023184B2 (ja) 2002-03-11 2007-12-19 昭和電工株式会社 発光体粒子及びその製造方法並びにその用途
US7514579B2 (en) 2002-06-13 2009-04-07 Johns Hopkins University Boronic chalcone derivatives and uses thereof
WO2004043371A2 (fr) 2002-11-08 2004-05-27 Irm Llc Procedes et compositions de modulation du facteur de transcription p53
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
EP1633749A4 (fr) 2003-02-13 2011-03-02 Us Gov Health & Human Serv Composes de deazaflavine et leurs methodes d'utilisation
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
KR20060073584A (ko) 2003-07-29 2006-06-28 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 아미노산 프로드럭
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
WO2005063774A1 (fr) 2003-12-22 2005-07-14 Johns Hopkins University Analogues d'aryle d'acide boronique
WO2005097820A1 (fr) 2004-04-06 2005-10-20 Korea Research Institute Of Bioscience And Biotechnology Peptides destines a inhiber la fonction mdm2
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
MXPA06013246A (es) 2004-05-18 2007-02-08 Hoffmann La Roche Nuevas imidazolinas cis.
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
NZ553646A (en) 2004-09-22 2010-07-30 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and p53
SG176463A1 (en) * 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
EA019566B1 (ru) * 2005-02-22 2014-04-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2
EP1891075B1 (fr) 2005-05-24 2011-10-19 Merck Serono SA Derives spiro tricycliques servant de modulateurs de crth2
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
JP5385125B2 (ja) 2006-03-22 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
EA016145B1 (ru) * 2006-08-30 2012-02-28 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Новые низкомолекулярные ингибиторы mdm2 и их применение
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US7737174B2 (en) * 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
KR101109438B1 (ko) 2006-09-21 2012-07-12 에프. 호프만-라 로슈 아게 항암제로서의 옥신돌 유도체
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
KR20090090383A (ko) 2006-12-14 2009-08-25 다이이찌 산쿄 가부시키가이샤 이미다조티아졸 유도체
WO2008106507A2 (fr) 2007-02-27 2008-09-04 University Of South Florida Peptide inhibiteur de mdm2/mdmx
AR065860A1 (es) 2007-03-29 2009-07-08 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (fr) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Antagonistes p53/mdm2/mdm4 sélectifs et à action double
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009037343A1 (fr) 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibiteurs de l'interaction entre mdm2 et p53
CZ301561B6 (cs) 2007-12-04 2010-04-14 Výzkumný ústav živocišné výroby, v. v. i. Prostredek pro prevenci a potlacování kokcidióz
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
EP2298778A4 (fr) 2008-06-12 2011-10-05 Daiichi Sankyo Co Ltd Dérivé d imidazothiazole ayant une structure cyclique de 4,7-diazaspiroý2.5¨octane
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
KR20120099462A (ko) * 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (fr) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nouveaux antagonistes de p53-mdm2/p53-mdm4 pour traiter une maladie de prolifération
SG184288A1 (en) 2010-04-09 2012-11-29 Univ Michigan Biomarkers for mdm2 inhibitors for use in treating disease
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
BR112013028983A2 (pt) 2011-05-11 2017-02-07 Sanofi Sa antagonistas mdm2 espiro-oxindol

Also Published As

Publication number Publication date
EA201390682A1 (ru) 2014-01-30
DOP2013000104A (es) 2013-10-15
EP2638046A2 (fr) 2013-09-18
AU2011326395B2 (en) 2016-01-07
KR20140027913A (ko) 2014-03-07
UA109464C2 (uk) 2015-08-25
CN103298818A (zh) 2013-09-11
WO2012065022A3 (fr) 2012-10-04
UY33725A (es) 2012-06-29
NI201300041A (es) 2013-12-17
MX2013005238A (es) 2013-09-02
TW201305177A (zh) 2013-02-01
CO6721010A2 (es) 2013-07-31
US8680132B2 (en) 2014-03-25
ECSP13012678A (es) 2013-08-30
ZA201304042B (en) 2014-02-26
US20120122947A1 (en) 2012-05-17
IL226275A0 (en) 2013-07-31
JP2014500870A (ja) 2014-01-16
WO2012065022A2 (fr) 2012-05-18
CN103298818B (zh) 2016-06-29
CR20130271A (es) 2013-10-03
EP2638046A4 (fr) 2014-06-25
KR101929188B1 (ko) 2018-12-17
US20140148494A1 (en) 2014-05-29
CA2817585A1 (fr) 2012-05-18
NZ611866A (en) 2015-04-24
US9302120B2 (en) 2016-04-05
AU2011326395A1 (en) 2013-05-09
TWI535723B (zh) 2016-06-01
PE20140408A1 (es) 2014-04-10
PH12013500955A1 (en) 2015-11-06
SG190230A1 (en) 2013-06-28
AR083849A1 (es) 2013-03-27
GT201300118A (es) 2014-08-05

Similar Documents

Publication Publication Date Title
MA34732B1 (fr) Spiro-oxindoles antagonistes de mdm2
MA33815B1 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
CA2883210C (fr) Composes aza bicycliques utilises comme agonistes du recepteur muscarinique m1
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
MA35576B1 (fr) Nouveaux composés
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
GB2511685A (en) Muscarinic m1 receptor agonists
MA34559B1 (fr) Formulation pour le traitement du cancer
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA44948A1 (fr) Inhibiteurs de bace 1
MA38190A2 (fr) Inhibiteurs d'autotaxine
CL2011000865A1 (es) Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras.
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA35064B1 (fr) Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
EP2801365A4 (fr) Utilisations de danshen (sauge rouge) ou de préparation à base de danshen dans l'élaboration des médicaments permettant de traiter les maladies liées à une fibrose hépatique.
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists
MA37955A1 (fr) Inhibiteurs de bêta-secrétase